Pharma
Aurobindo Pharma Ltd
AUROPHARMA · NSE · INE406A01037Thursday, 10 Sept 202610:16 am
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE9.9%
ROCE12.7%
ROE9.9%
1Y Return+43.37%
Avg. Volume1.0M
Price Chart
52-Week Range
About
Aurobindo Pharma Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹1,674.1
52W High / Low₹1,717 / ₹1,061.3
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE9.9%
1Y Return+43.37%
Day Change-0.94%
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹34,935 Cr | ₹33,653 Cr | ₹31,724 Cr | ||||||||||
| Expenses | ₹27,854 Cr | ₹26,783 Cr | ₹25,164 Cr | ||||||||||
| Operating Profit | ₹7,081 Cr | ₹6,870 Cr | ₹6,560 Cr | ||||||||||
| OPM % | 20.0% | 20.0% | 21.0% | ||||||||||
| Other Income | ₹586 Cr | ₹404 Cr | ₹613 Cr | ||||||||||
| Depreciation | ₹1,859 Cr | ₹1,778 Cr | ₹1,649 Cr | ||||||||||
| Interest | ₹388 Cr | ₹384 Cr | ₹457 Cr | ||||||||||
| Profit Before Tax | ₹5,420 Cr | ₹5,112 Cr | ₹5,066 Cr | ||||||||||
| Tax | ₹1,709 Cr | ₹1,609 Cr | ₹1,582 Cr | ||||||||||
| Net Profit | ₹3,711 Cr | ₹3,503 Cr | ₹3,484 Cr | ||||||||||
| EPS (₹) | 64.1 | 60.3 | 60.0 | ||||||||||
| Dividend Payout % | — | 7% | 0% |
Financial history locked
Register freeRegister free to see 10 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹9,150 Cr | ₹8,853 Cr | ₹8,646 Cr | ₹8,286 Cr | |||||||||
| Expenses | ₹7,271 Cr | ₹7,103 Cr | ₹6,873 Cr | ₹6,608 Cr | |||||||||
| Operating Profit | ₹1,880 Cr | ₹1,750 Cr | ₹1,773 Cr | ₹1,678 Cr | |||||||||
| OPM % | 21.0% | 20.0% | 21.0% | 20.0% | |||||||||
| Depreciation | ₹487 Cr | ₹479 Cr | ₹465 Cr | ₹429 Cr | |||||||||
| Interest | ₹102 Cr | ₹98 Cr | ₹93 Cr | ₹95 Cr | |||||||||
| Net Profit | ₹1,032 Cr | ₹921 Cr | ₹910 Cr | ₹848 Cr | |||||||||
| EPS (₹) | 18.0 | 15.9 | 15.7 | 14.6 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹58 Cr | ₹58 Cr | ₹59 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹37,833 Cr | ₹32,595 Cr | ₹29,784 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹8,073 Cr | ₹8,263 Cr | ₹6,648 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹12,232 Cr | ₹8,566 Cr | ₹8,226 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹58,196 Cr | ₹49,482 Cr | ₹44,717 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹17,407 Cr | ₹14,794 Cr | ₹14,493 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹1,051 Cr | ₹252 Cr | ₹372 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹34,525 Cr | ₹29,536 Cr | ₹25,983 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹58,196 Cr | ₹49,482 Cr | ₹44,717 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 10 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹5,526 Cr | ₹-2,630 Cr | ₹-1,269 Cr | ₹1,628 Cr |
| FY25 | ₹3,925 Cr | ₹-1,866 Cr | ₹120 Cr | ₹2,178 Cr |
| FY24 | ₹2,435 Cr | ₹-4,242 Cr | ₹800 Cr | ₹-1,007 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 | ||||
| FY20 | ||||
| FY19 | ||||
| FY18 | ||||
| FY17 | ||||
| FY16 | ||||
| FY15 |
Cash flow history locked
Register freeRegister free to see 10 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-03Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE Filing2026-08-06Aurobindo Pharma Ltd (BOM:524804) (Q1 2027) Earnings Call Highlights: Record Revenue Growth and ...GuruFocus.com2026-08-05What to Expect From Aurobindo Pharma Ltd (NSE:AUROPHARMA) Q1 2027 EarningsGuruFocus.com
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.